Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DePHEAT-PJI: Phage Therapy in Periprosthetic Joint Infections
NCT07698002Phase 3Not yet recruiting
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Jul 2026
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in periprosthetic joint infection (PJI) comparing Standard of care (DAIR + Antibiotics) with Bacteriophage treatment + DAIR + Antibiotics (2 arms). Primary endpoints: Incidence of treatment emergent adverse events at 12 months and Evaluation of the feasibility of the trial design at 3 months. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
bacteriophages
03
Conditions
periprosthetic joint infection (PJI)
Beyond the preview
Go deeper on NCT07698002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07698002.